Who is the CEO of Dt&cro?

According to the DART company overview, Dt&cro's representative director is 박채규 (name as registered in Korean). The company was founded on 2017-04-03.

Where is Dt&cro listed?

Dt&cro trades on the Korea Exchange KOSDAQ market under the ticker 383930. Its fiscal year ends in December.

Does Dt&cro pay a dividend?

Dt&cro did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Dt&cro have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Litigation (lawsuit filed or ruled on, disclosed in the past 180 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Supply contract (single sales or supply contract disclosed in the past 30 days). These are factual flags, not investment advice.

Which companies are in the same industry as Dt&cro?

Under the Korean Standard Industrial Classification recorded on DART, Dt&cro is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.

Dt&cro KRX:383930KOSDAQ

디티앤씨알오 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days2

Articles tracked31since Sep 11

In Q3 2026, Dt&cro reported revenue of ₩14.5bn, up 15.7% year on year, and operating profit of ₩433m. Dt&cro (디티앤씨알오) appeared in 0 Korean news articles and 2 DART filings over the past seven days.

Filing signals Turnaround Supply contract Litigation Screener

Dt&cro quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q3 2026	₩14.5bn	+15.7%	₩433m margin 3.0%	−₩315m
Q2 2026	₩11.3bn	+12.3%	−₩6.6bn margin −58.1%	−₩4.1bn
Q1 2026	₩10.1bn	+0.2%	−₩3.6bn margin −35.4%	−₩13.8bn
Q4 2025 derived	₩15.0bn	+29.2%	₩621m margin 4.1%	₩2.7bn
Q3 2025	₩12.6bn	+19.6%	−₩905m margin −7.2%	−₩2.0bn
Q2 2025	₩10.1bn	+38.6%	−₩2.0bn margin −19.6%	₩710m
Q1 2025	₩10.1bn	+53.6%	−₩3.5bn margin −34.5%	−₩4.3bn
Q4 2024 derived	₩11.6bn	+1448.0%	−₩543m margin −4.7%	₩9.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Dt&cro top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest Dt&cro news Korean headlines

Oct 1915:58
DT&CRO strengthens integrated full-cycle service for improved drug and complex formulation development
뉴스핌
1 more on this story · 1 outlets
- DT&CRO strengthens integrated clinical service for improved drugs바이오타임즈 · Oct 19 16:33
Oct 1914:13
Paselbio reveals CAR-MIL multiple myeloma therapeutic research results at ESMO and others including DT&CRO and Microdigital
글로벌경제신문Micro Digital Vaxcell-Bio Therapeutics
4 more on this story · 3 outlets
- Paselbio reveals CAR-MIL multiple myeloma therapeutic research results at ESMO뉴스타운 · Oct 19 11:05
- Paselbio unveils CAR-MIL multiple myeloma therapeutic at ESMO핀포인트뉴스 · Oct 19 11:09
- Paselbio presents CAR-MIL multiple myeloma therapeutic research poster at ESMO이데일리 · Oct 19 11:29
- Paselbio presents CAR-MIL multiple myeloma therapeutic research poster at ESMO이데일리 · Oct 19 11:30
Oct 1907:14

Listed company at crossroads: DT&CRO⑥ Chairman Park Chae-gyu receives special bonus alone amid liquidity crisis
아시아경제
Oct 1616:06
BIO Talk: L&C Bio completes 144.7 billion won rights offering subscription from existing shareholders, and others including DT&CRO and Celtrics
글로벌경제신문L&C Bio
2 more on this story · 2 outlets
- L&C Bio completes rights offering subscription from existing shareholders at 144.7 billion won뉴스핌 · Oct 16 10:41
- L&C Bio completes rights offering subscription from existing shareholders at 144.7 billion won, plans Dongtan integrated center investmentEBN · Oct 16 14:07
Oct 1609:23

DT&CRO launches nonclinical integrated assessment service for anticoagulation and blood circulation improvement materials
팜뉴스
Oct 1608:57

DT&CRO operates anticoagulation and blood circulation improvement integrated assessment
뉴스핌
Oct 1608:52

DT&CRO operates integrated nonclinical assessment service
컨슈머타임스
Oct 1516:39

DT&CRO pursues advancement of AI-based digital pathology
뉴스핌
Oct 1515:34

DT&CRO to build AI-based pathology by early next year through digital transformation of nonclinical toxicity assessment
머니투데이
Oct 1515:28

DT&CRO adopts AI for nonclinical pathology interpretation, promotes toxicity test data integration
바이오타임즈
Oct 710:42
MajorDT&CRO expands nonclinical testing good practice testing items
이데일리Clinical trial
2 more on this story · 2 outlets
- DT&CRO expands nonclinical testing good practice testing items이데일리증권 · Oct 7 10:42
- DT&CRO expands nonclinical testing good practice testing items이데일리 · Oct 7 10:44
Oct 708:21

DT&CRO expands GLP certification, strengthens nonclinical testing capabilities
메디파나뉴스
Oct 706:45
DT&CRO expands GLP testing items, newly certifies phototoxicity and multi-ion channel testing
더바이오
2 more on this story · 2 outlets
- DT&CRO expands GLP testing items, newly certifies phototoxicity and multi-ion channel testing뉴스핌 · Oct 7 09:20
- DT&CRO expands GLP testing scope with phototoxicity and multi-ion channel testing certification바이오타임즈 · Oct 7 14:28
Oct 215:36

DT&CRO expands nonclinical analysis services, supports metabolite analysis using TK samples
더바이오
Oct 214:59

DT&CRO signs MOU with Korean Innovation Pharmaceutical Consortium on new drug development support
뉴스핌
Oct 214:53
DT&CRO cooperates with KIMCo and Korea University Guro Hospital, expands full-cycle new drug development support
바이오타임즈
1 more on this story · 1 outlets
- DT&CRO cooperates with KIMCo Foundation and Korea University Guro Hospital, expands new drug development support이데일리 · Oct 2 16:11
Oct 214:39

DT&CRO strengthens full-cycle CRO competitiveness, expands industry-academia collaboration
더바이오
Oct 213:33

Expanding industry-academia cooperation, DT&CRO strengthens full-cycle CRO capabilities for new drug development
파이낸셜뉴스
Oct 208:06

Listed company at crossroads: DT&CRO④ unable to recover receivables from customers, faces going concern risk
아시아경제
Sep 2311:27

KIMCo Foundation, DT&CRO cooperate on pharma and biotech startup support, backing entire new drug development cycle
바이오타임즈
Sep 2310:36

KIMCo Foundation and DT&CRO cooperate on pharma and biotech commercialization support
핀포인트뉴스
Sep 2310:18
KIMCo Foundation and DT&CRO join hands to support new drug development for pharma and biotech startups
PRESS9
3 more on this story · 3 outlets
- KIMCo Foundation and DT&CRO provide tailored support for pharma and biotech startups간호사신문 · Sep 23 10:44
- KIMCo Foundation and DT&CRO to support new drug development for startups메드월드뉴스 · Sep 23 12:43
- KIMCo Foundation and DT&CRO to support new drug development for pharma and biotech startups한국식품의약신문 · Sep 23 16:04

Articles per day 2 weeks

Company profile

CEO: 박채규
Industry: Medical & pharmaceutical R&D
Founded: 2017-04-03
Fiscal year-end: December
Head office: 경기도 용인시
Website: dtncro.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Same industry Medical & pharmaceutical R&D

All in industry

Company	Latest quarter op. profit	Articles 30d
Alteogen	–	255
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
SillaJen	–	44
OliX Pharmaceuticals	–	42
Qurient	−₩7.0bn	41
GI Innovation	–	41

Compare Dt&cro side by side with these companies

Dt&cro DART filings

Nov 1313:48

Corrected filing: Execution of exclusive sales/supply contract (voluntary disclosure)
Contracts & investment
Nov 1313:04

Quarterly report (September 2026)
Other
Nov 618:10

Corrected filing: Execution of exclusive sales/supply contract (voluntary disclosure)
Contracts & investment
Oct 3014:12

Corrected filing: Execution of exclusive sales/supply contract (voluntary disclosure)
Contracts & investment
Oct 715:53

Corrected filing: Court judgments and decisions on lawsuits, etc. (claims of certain amounts or more)
Risk & warnings
Sep 3015:55

Court judgments and rulings (claims of certain amounts or higher)
Risk & warnings
Sep 3014:31

Court judgments and rulings (claims of certain amounts or higher)
Risk & warnings
Sep 3011:24

Corrected attachment: Court judgments and decisions on lawsuits, etc. (claims of certain amounts or more)
Risk & warnings
Sep 2915:19

Corrected filing: Adjustment of exercise price for warrant subscription rights
Other
Sep 2915:15

Correction to filing: Adjustment of conversion price
Other
Sep 2817:55

Corrected filing: Court judgments and decisions on lawsuits, etc. (claims of certain amounts or more)
Risk & warnings
Sep 2817:49

Corrected filing: Court judgments and decisions on lawsuits, etc. (claims of certain amounts or more)
Risk & warnings

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Dt&cro FAQ

Who is the CEO of Dt&cro?: According to the DART company overview, Dt&cro's representative director is 박채규 (name as registered in Korean). The company was founded on 2017-04-03.
Where is Dt&cro listed?: Dt&cro trades on the Korea Exchange KOSDAQ market under the ticker 383930. Its fiscal year ends in December.
What were Dt&cro's latest quarterly results?: In Q3 2026, Dt&cro reported revenue of ₩14.5bn, up 15.7% year on year, and operating profit of ₩433m. Figures come from reports filed on DART.
Does Dt&cro pay a dividend?: Dt&cro did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Dt&cro have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Litigation (lawsuit filed or ruled on, disclosed in the past 180 days); Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Supply contract (single sales or supply contract disclosed in the past 30 days). These are factual flags, not investment advice.
Which companies are in the same industry as Dt&cro?: Under the Korean Standard Industrial Classification recorded on DART, Dt&cro is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.